RJA
CLGN icon

Raymond James & Associates’s CollPlant Biotechnologies CLGN Stock Holding History

Raymond James & Associates’s Portfolio CLGN Stock Details CLGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-20,800
Closed -$441K – 4139
2021
Q2 		$441K Hold
20,800
– – ﹤0.01% 3177
2021
Q1 		$280K Buy
+20,800
New +$314K ﹤0.01% 3406

Other funds holding CLGN

IMOV
Investment Management of Virginia Richmond, Virginia $526M AUM 3.23% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
BFEC
Benjamin F. Edwards & Company St. Louis, Missouri $5.69B AUM 15.37% 1-Year Est. Return
WC
Weil Company San Diego, California $445M AUM 14.95% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Raymond James & Associates's CLGN Position: Q3 2021 in Review

Raymond James & Associates sold out of CollPlant Biotechnologies (CLGN) in Q3 2021, closing a stake of 20,800 shares — an estimated $441K sold.

Raymond James & Associates first reported a position in CLGN in Q1 2021 and held it in 2 quarters. The position peaked at $441K in Q2 2021. 15 funds tracked by Wall St. Rank hold CLGN as of Q3 2021.

  • Raymond James & Associates reported no remaining CollPlant Biotechnologies position as of Q3 2021 after selling out during the quarter.
  • Raymond James & Associates sold 20,800 CollPlant Biotechnologies shares in Q3 2021, an estimated $441K.
  • Raymond James & Associates first reported a position in CollPlant Biotechnologies in Q1 2021 and held it in 2 quarters.
  • Raymond James & Associates's CollPlant Biotechnologies position peaked at $441K in Q2 2021.
  • 15 funds tracked by Wall St. Rank held CollPlant Biotechnologies as of Q3 2021.

Based on Raymond James & Associates's 13F filing for Q3 2021, filed 2 Nov 2021.